Brimonidine（CAS:59803-98-4)

Brimonidine, known as research code UK-14304 with CAS number 59803-98-4, is the most widely utilized highly selective α2 adrenergic agonist in ophthalmic pharmacology. Featuring precise target specificity, dual intraocular pressure (IOP) lowering mechanisms and unique neuroprotective potency, it has become an essential core research API for universities, CRO laboratories and ophthalmic pharmaceutical enterprises focusing on glaucoma, optic neuropathy, myopia prevention and ocular surface inflammation research. Appearing as yellow solid powder, it possesses stable physicochemical properties and resists oxidative degradation under normal temperature and light shielding. With qualified HPLC purity and strictly controlled related impurities, heavy metals and residual solvents, it dissolves well in DMSO and aqueous buffer solutions, fully supporting full-process research scenarios including in vitro receptor binding assays, ocular cell culture, glaucoma animal modeling, myopia model intervention and high-throughput compound screening with excellent batch consistency and experimental repeatability.

Different from traditional β-blockers and prostaglandin ophthalmic drugs, Brimonidine delivers dual IOP-lowering advantages with exclusive pharmacological characteristics. It selectively activates α2 receptors on ciliary epithelium, downregulates adenylate cyclase activity and significantly suppresses excessive aqueous humor production to reduce intraocular fluid accumulation at the source. Meanwhile, it dilates the uveoscleral drainage pathway to accelerate aqueous humor outflow and intraocular metabolite excretion, achieving stable and long-term IOP reduction through dual synergistic pathways. Pharmacological data verify its high affinity for α2A, α2B and α2C receptors with Ki values of 2.7 nM, 52 nM and 44 nM respectively, while exhibiting negligible binding to α1 receptors. This ultra-high subtype selectivity avoids common side effects of traditional adrenergic agents such as mydriasis, conjunctival hyperemia and heart rate fluctuation, ensuring superior ocular targeting safety. Its hypotensive effect peaks at 2 hours after administration with mild in vivo metabolism, suitable for long-term clinical and experimental intervention.

Beyond classic IOP-lowering efficacy, Brimonidine possesses differentiated multi-dimensional research value and has become a popular tool compound in cutting-edge ophthalmic studies. Firstly, it provides retinal neuroprotection by upregulating brain-derived neurotrophic factor (BDNF), inhibiting retinal ganglion cell apoptosis induced by high intraocular pressure, relieving optic nerve ischemic oxidative damage and delaying visual field defect progression, serving as a core control material for normal-tension glaucoma and optic neuropathy research. Secondly, it exerts reliable myopia control effects; abundant animal studies confirm that it inhibits excessive axial elongation and regulates scleral remodeling, effectively intervening form-deprivation myopia progression and providing critical experimental support for adolescent myopia mechanism research and new drug development. Thirdly, it improves ocular surface inflammation and erythema by constricting superficial ocular microvessels and reducing pro-inflammatory cytokine release, supporting studies on ocular surface microenvironment disorders and rosacea-related facial erythema.

In terms of scientific research and industrial value, Brimonidine adopts mature synthetic routes and refined purification systems to efficiently remove structural analog impurities, ensuring uniform biological activity across batches. Available in milligram to kilogram specifications, it fully meets the demands of laboratory mechanism exploration, pilot formulation development and preclinical efficacy verification. With minimal local irritation, low systemic absorption, mild side effects and a wide safety experimental window, it is ideal for long-term animal model intervention. Against the backdrop of growing global patients with glaucoma, high myopia and optic neurodegeneration, traditional ophthalmic drugs are limited by single-target efficacy. In contrast, Brimonidine integrates IOP reduction, neuroprotection, anti-inflammation and myopia inhibition, making it a core reference compound for multi-target ophthalmic innovative drug R&D. With clear pharmacological pathways, comprehensive in vitro and in vivo data and mature application systems, UK-14304 maintains irreplaceable rigid research value in ophthalmic basic pharmacology, generic drug formulation optimization and innovative target screening, promising broad and stable long-term application prospects in the global pharmaceutical research market.